TIME 100 Most Influential People of 2025
The Age of CRISPR
Sam Altman-backed Retro Biosciences to raise $1bn for project to extend human life
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy
Using AI to design small molecule drugs is tough. Here are five companies trying to crack the code.
Combining AI and Crispr Will Be Transformational
Ataraxis AI Launches to Transform Precision Medicine Beginning with World’s First AI-native Cancer Diagnostic
Roche Bets Up to $1 Billion to Solve Gene Therapy’s Big Problem
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases
Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing
With AI warning, Nobel winner joins ranks of laureates who’ve cautioned about the risks of their own work
Augmenting Humans: From bionic limbs, to smart skin and robot helpers
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
The small-town Nobel Prize winner who wants to cure Alzheimer’s in 10 years
10 Most Innovative People of the Last 10 Years
Fareed Zakaria GPS: The gene editing revolution
The race to build better CRISPR delivery vehicles is heating up
Meet the man who combines science, technology and magic to understand proteins
AI gene editing tools have power to modify human DNA, say researchers
AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality
How crops are being disaster-proofed
New medicine could prevent disease before it begins — but at a cost
Generative A.I. Arrives in the Gene Editing World of CRISPR
Artificial intelligence is taking over drug development
Sam Altman’s mission to increase human lifespan with a $180 million shipping container experiment at Retro Biosciences
Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing
Gene-editing pioneer calls for big investment in Crispr technology
Biotech VCs See Room for More Growth in Obesity Drug Market
Antibiotic Resistance is a Looming Crisis. CRISPR May Hold the Answer
BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers
BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
The Age of CRISPR: Engineering the Future of Genetic Medicine
Innovative Genomics Institute and Danaher Join Forces to Accelerate and Scale Up the Development of CRISPR Cures
Gene Editing Needs to Be for Everyone
The Most Secretive Longevity Lab Finally Opens Its Doors
The First Crispr Therapy Is Just the Start of the Gene-Editing Revolution
FDA approves first gene-editing treatment for human illness
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
FDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease
FDA approves two sickle cell therapies, including first CRISPR medicine
